Abbott Korea launches film-type hepatitis B treatment for the first time

Published: 2015-10-14 16:02:15

Updated: 2015-10-14 16:17:20

Today, Abbott Korea(CEO Yoo-seok Jung) launched ‘Filclude ODF(generic name: entecavir),’ the first film-type hepatitis B treatment, in respective 0.5mg and 1mg.

‘Filclude ODF,’ a film-type drug which innovatively improved the existing hepatitis B treatment, entecavir,’ can be administered by melting it on one’s tongue unlike other drug types requiring water.

Since the drug is easy to carry ar...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.